- Home
- OPY vs KURA Comparison
OPY vs KURA Comparison
Compare OPY & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- KURA
- Stock Information
- Founded
- OPY 1881
- KURA 2014
- Country
- OPY United States
- KURA United States
- Employees
- OPY N/A
- KURA N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- KURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OPY Finance
- KURA Health Care
- Exchange
- OPY Nasdaq
- KURA Nasdaq
- Market Cap
- OPY 696.7M
- KURA 561.9M
- IPO Year
- OPY N/A
- KURA N/A
- Fundamental
- Price
- OPY $70.68
- KURA $6.36
- Analyst Decision
- OPY
- KURA Strong Buy
- Analyst Count
- OPY 0
- KURA 12
- Target Price
- OPY N/A
- KURA $24.50
- AVG Volume (30 Days)
- OPY 78.1K
- KURA 1.4M
- Earning Date
- OPY 07-25-2025
- KURA 08-07-2025
- Dividend Yield
- OPY 1.01%
- KURA N/A
- EPS Growth
- OPY 84.56
- KURA N/A
- EPS
- OPY 6.74
- KURA N/A
- Revenue
- OPY $1,358,354,000.00
- KURA $67,991,000.00
- Revenue This Year
- OPY N/A
- KURA $125.04
- Revenue Next Year
- OPY N/A
- KURA $83.75
- P/E Ratio
- OPY $10.46
- KURA N/A
- Revenue Growth
- OPY 12.80
- KURA N/A
- 52 Week Low
- OPY $47.39
- KURA $5.41
- 52 Week High
- OPY $73.12
- KURA $22.07
- Technical
- Relative Strength Index (RSI)
- OPY 69.63
- KURA 58.77
- Support Level
- OPY $65.50
- KURA $6.08
- Resistance Level
- OPY $71.05
- KURA $6.70
- Average True Range (ATR)
- OPY 1.51
- KURA 0.29
- MACD
- OPY 0.28
- KURA 0.08
- Stochastic Oscillator
- OPY 88.03
- KURA 85.27
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.